Drug class
Farnesoid X receptor (FXR) agonist; bile-acid analogue
Mechanism of action
Activates FXR in the liver and intestine, regulating bile-acid synthesis and transport and reducing hepatic bile-acid accumulation. It also modulates pathways involved in lipid and glucose metabolism.
General use cases
- Historical US indication: treatment of primary biliary cholangitis in adults in combination with ursodeoxycholic acid when response to UDCA is inadequate, or as monotherapy when UDCA is not tolerated. US FDA accelerated approval was withdrawn in 2025; do not present as currently authorised in the US.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
